发展中国家的药物警戒
Pharmacovigilance in developing countries.
作者信息
Pirmohamed Munir, Atuah Kwame N, Dodoo Alex N O, Winstanley Peter
出版信息
BMJ. 2007 Sep 8;335(7618):462. doi: 10.1136/bmj.39323.586123.BE.
Abstract
Requires collaboration between stakeholders to develop novel models of funding
摘要
需要利益相关者之间开展合作以开发新的资金筹集模式
相似文献
1
Pharmacovigilance in developing countries.发展中国家的药物警戒
BMJ. 2007 Sep 8;335(7618):462. doi: 10.1136/bmj.39323.586123.BE.
2
Capacity for a global vaccine safety system: the perspective of national regulatory authorities.全球疫苗安全体系的能力：国家监管机构的观点。
Vaccine. 2012 Jul 13;30(33):4953-9. doi: 10.1016/j.vaccine.2012.05.045. Epub 2012 May 30.
3
The role of the pharmaceutical industry in disseminating pharmacovigilance practice in developing countries.制药行业在发展中国家传播药物警戒实践中的作用。
Food Drug Law J. 2008;63(3):701-11.
4
Recommendations from the Thirty-seventh Annual Meeting of National Pharmacovigilance Centres.国家药物警戒中心第三十七届年会的建议
Int J Risk Saf Med. 2015;27(3):143-52. doi: 10.3233/JRS-140652.
5
Drug safety: reporting systems for the general public.药物安全：面向公众的报告系统。
BMJ. 2012 Aug 7;345:e4916. doi: 10.1136/bmj.e4916.
6
Adverse drug reactions in developing countries.发展中国家的药物不良反应
J Coll Physicians Surg Pak. 2004 May;14(5):325.
7
Quality check of spontaneous adverse drug reaction reporting forms of different countries.不同国家自发药物不良反应报告表的质量检查。
Pharmacoepidemiol Drug Saf. 2010 Nov;19(11):1181-5. doi: 10.1002/pds.2004.
8
Biovigilance and pharmacovigilance for haemophilia.血友病的生物监测与药物警戒
Haemophilia. 2010 Jul;16 Suppl 5:17-21. doi: 10.1111/j.1365-2516.2010.02288.x.
9
Adverse drug reaction reporting and monitoring: role of practising physicians.药品不良反应报告与监测：执业医师的作用
J Assoc Physicians India. 2000 Aug;48(8):852.
10
Serious adverse drug reactions in older adults notified to pharmacovigilance.向药物警戒报告的老年人严重药物不良反应。
Therapie. 2012 Sep-Oct;67(5):465-70. doi: 10.2515/therapie/2012060. Epub 2012 Dec 18.
引用本文的文献
1
Global trends in pharmacovigilance-related events: a 30-year analysis from the 2019 global burden of disease study.全球药物警戒相关事件趋势：2019 年全球疾病负担研究三十年分析。
Int J Clin Pharm. 2024 Oct;46(5):1076-1090. doi: 10.1007/s11096-024-01738-6. Epub 2024 May 10.
2
Incidence and Predictors of Severe Adverse Drug Reactions among Patients on Antiretroviral Drugs in Harari Regional State, Eastern Ethiopia.埃塞俄比亚东部哈拉里地区接受抗逆转录病毒药物治疗患者严重药物不良反应的发生率及预测因素
Can J Infect Dis Med Microbiol. 2024 Jan 19;2024:5580728. doi: 10.1155/2024/5580728. eCollection 2024.
3
Enhancing Pharmacovigilance in Côte d'Ivoire: Impact of GSK's Training and Mentoring Pilot Project in the Abidjan Region.加强科特迪瓦的药物警戒：葛兰素史克在阿比让地区的培训与指导试点项目的影响。
Drug Saf. 2024 Feb;47(2):147-159. doi: 10.1007/s40264-023-01368-3. Epub 2023 Nov 15.
4
Adverse Events to SARS-CoV-2 (COVID-19) Vaccines and Policy Considerations that Inform the Funding of Safety Surveillance in Low- and Middle-Income Countries: A Mixed Methods Study.SARS-CoV-2（COVID-19）疫苗的不良事件与为中低收入国家提供安全监测资金的政策考量：一项混合方法研究。
Drug Saf. 2023 Apr;46(4):357-370. doi: 10.1007/s40264-023-01279-3. Epub 2023 Feb 22.
5
A Systematic Review of Pharmacovigilance Systems in Developing Countries Using the WHO Pharmacovigilance Indicators.发展中国家药物警戒系统的系统评价：使用世卫组织药物警戒指标。
Ther Innov Regul Sci. 2022 Sep;56(5):717-743. doi: 10.1007/s43441-022-00415-y. Epub 2022 Jun 3.
6
Leveraging Experience From Active TB Drug-Safety Monitoring and Management for Monitoring Active Antiretroviral Toxicity.利用活动性结核药物监测和管理中的经验来监测抗逆转录病毒药物的毒性。
Glob Health Sci Pract. 2022 Apr 29;10(2). doi: 10.9745/GHSP-D-21-00595. Print 2022 Apr 28.
7
A qualitative exploration of pharmacovigilance policy implementation in Jordan, Oman, and Kuwait using Matland's ambiguity-conflict model.采用 Matland 的歧义-冲突模型对约旦、阿曼和科威特的药物警戒政策实施进行定性探索。
Global Health. 2021 Aug 30;17(1):97. doi: 10.1186/s12992-021-00751-y.
8
Medication safety knowledge, attitude, and practice among hospital pharmacists in tertiary care hospitals in Saudi Arabia: a multi-center study.沙特阿拉伯三级医院药剂师的用药安全知识、态度及实践：一项多中心研究。
Arch Public Health. 2021 Jul 12;79(1):130. doi: 10.1186/s13690-021-00616-1.
9
Recommendations for acceleration of vaccine development and emergency use filings for COVID-19 leveraging lessons from the novel oral polio vaccine.利用新型口服脊髓灰质炎疫苗的经验教训，加速COVID-19疫苗研发和紧急使用申请的建议。
NPJ Vaccines. 2021 Apr 22;6(1):63. doi: 10.1038/s41541-021-00325-4.
10
Adverse drug reaction profile in Amravati region of India: A pharmacovigilance study.印度阿姆拉瓦蒂地区的药物不良反应概况：一项药物警戒研究。
J Pharm Bioallied Sci. 2020 Apr-Jun;12(2):155-162. doi: 10.4103/jpbs.JPBS_226_19. Epub 2020 Apr 10.
本文引用的文献
1
Rosiglitazone and implications for pharmacovigilance.罗格列酮及其对药物警戒的意义。
BMJ. 2007 Jun 16;334(7606):1233-4. doi: 10.1136/bmj.39245.502546.BE.
2
Ethnicity and adverse drug reactions.种族与药物不良反应。
BMJ. 2006 May 20;332(7551):1163-4. doi: 10.1136/bmj.332.7551.1163.
3
Beyond registration--measuring the public-health potential of new treatments for malaria in Africa.超越注册——衡量非洲疟疾新疗法的公共卫生潜力。
Lancet Infect Dis. 2006 Jan;6(1):46-52. doi: 10.1016/S1473-3099(05)70326-1.
4
Clinical pharmacology: special safety considerations in drug development and pharmacovigilance.临床药理学：药物研发与药物警戒中的特殊安全性考量
Drug Saf. 2004;27(8):535-54. doi: 10.2165/00002018-200427080-00006.
5
Patents and access to drugs in developing countries: an ethical analysis.发展中国家的专利与药品可及性：一项伦理分析。
Dev World Bioeth. 2004 May;4(1):58-75. doi: 10.1111/j.1471-8731.2004.00067.x.
6
Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection.在罗阿丝虫感染流行地区用伊维菌素大规模治疗盘尾丝虫病后的严重反应。
Lancet. 1997 Jul 5;350(9070):18-22. doi: 10.1016/S0140-6736(96)11094-1.
7
Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994.药物警戒：失而复得还是推迟到来？1994年威廉·威瑟林讲座
J R Coll Physicians Lond. 1995 Jan-Feb;29(1):41-9.
Zotero 插件